Contributions
Abstract: 187
Type: Hot Topic
Abstract Category: N/A
Both depression and fatigue are common in people with MS (pwMS). Major depression may affect up to 50% of pwMS over the course of their lifetime while fatigue ranks amongst the top three disabling symptoms identified by pwMS. Fatigue may be part of the syndromal diagnosis of depression, but it may also be present as a separate clinical phenomenon. Furthermore, fatigue may be physical, cognitive or a combination of both. Successful management will depend on teasing out these various entities, although it is recognized that they may all occur concurrently in the same person.MS-related depression responds to cognitive behaviour therapy (CBT), Mindfulness Based Therapy and antidepressant medication, although the latter may come with side effects that can affect compliance. Fatigue may also be treated pharmacologically with a different set of drugs. There is pharmacologic overlap with the antidepressant agent, buproprion, which is also considered activating given its dopaminergic mediating properties. More recent evidence suggests that CBT may also be effective in reducing fatigue in pwMS even in the absence of - depression.
Disclosure: Grant support from the MS Society of Canada and the Canadian Institute of Health Research. Speakers honoraria from Sanofi-Genzyme, Teva, Roche and Biogen. Advisory Board membership with Akili Interactive.
Abstract: 187
Type: Hot Topic
Abstract Category: N/A
Both depression and fatigue are common in people with MS (pwMS). Major depression may affect up to 50% of pwMS over the course of their lifetime while fatigue ranks amongst the top three disabling symptoms identified by pwMS. Fatigue may be part of the syndromal diagnosis of depression, but it may also be present as a separate clinical phenomenon. Furthermore, fatigue may be physical, cognitive or a combination of both. Successful management will depend on teasing out these various entities, although it is recognized that they may all occur concurrently in the same person.MS-related depression responds to cognitive behaviour therapy (CBT), Mindfulness Based Therapy and antidepressant medication, although the latter may come with side effects that can affect compliance. Fatigue may also be treated pharmacologically with a different set of drugs. There is pharmacologic overlap with the antidepressant agent, buproprion, which is also considered activating given its dopaminergic mediating properties. More recent evidence suggests that CBT may also be effective in reducing fatigue in pwMS even in the absence of - depression.
Disclosure: Grant support from the MS Society of Canada and the Canadian Institute of Health Research. Speakers honoraria from Sanofi-Genzyme, Teva, Roche and Biogen. Advisory Board membership with Akili Interactive.